ORANGE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, being held in New York, New York, including a presentation on Wednesday, Sept. 13, at 1:35 p.m. EDT.
A webcast and replay of the presentations will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/.
About Alignment Health
Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health is a tech-enabled Medicare Advantage company that offers more than 40 benefits-rich, value-driven plans that serve 52 counties across six states. The company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. Based in California, the company’s mission-focused team makes high-quality, low-cost care a reality for members every day. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.
Investor Contact
Harrison Zhuo
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Maggie Habib
mPR, Inc. for Alignment Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$19.48 |
Daily Change: | 0.05 0.26 |
Daily Volume: | 2,395,400 |
Market Cap: | US$3.730B |
April 15, 2025 February 28, 2025 February 27, 2025 January 13, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load